• About CPF
    Company Profiles Awards Global Collaboration Media Center Subsidiary
  • Products & Services
    API and intermediates Dosage Services
  • R&D
  • News
    Company News Industry News
  • Contact Us
  • 中
About CPF Products & Services R&D News Contact Us
  • Company News
  • Industry News

Recent developments of Sugammadex Sodium in the wake period of anesthesia

Sugammadex Sodiumis a novel antagonist of selective non-depolarizing muscle relaxants (myorelaxants), which was first reported in humans in 2005 and has since been used clinically in Europe, the United States and Japan. Compared with traditional anticholinesterase drugs, it can antagonize deep

By CPF on 2021-09-27
READ MORE→
Recent developments of Sugammadex Sodium in the wake period of anesthesia

2021 FDA New Drug Approvals 1Q-3Q

Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA's Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of the science used to creat

By CPF on 2021-09-27
READ MORE→
2021 FDA New Drug Approvals 1Q-3Q

Recent developments of Sugammadex Sodium in the wake period of anesthesia

Sugammadex Sodiumis a novel antagonist of selective non-depolarizing muscle relaxants (myorelaxants), which was first reported in humans in 2005 and has since been used clinically in Europe, the United States and Japan. Compared with traditional anticholinesterase drugs, it can antagonize deep

By CPF on 2021-09-27
READ MORE→
Recent developments of Sugammadex Sodium in the wake period of anesthesia

Which tumors are thalidomide effective in treating!

Thalidomideis effective in treating these tumors!1. In which solid tumors can thalidomide be used.1.1. lung cancer.1.2. Prostate cancer.1.3. nodal rectal cancer.1.4. hepatocellular carcinoma.1.5. Gastric cancer.2. Thalidomide in tumor cachexiaOncologic cachexia, an advanced cancer syndrome cha

By CPF on 2021-09-02
READ MORE→
Which tumors are thalidomide effective in treating!

Apixaban and Rivaroxaban

In recent years, the sales ofapixabanhave grown rapidly, and the global market has already surpassedrivaroxaban. Because Eliquis (apixaban) has an advantage over warfarin in preventing stroke and bleeding, and Xarelto (Rivaroxaban) only showed non-inferiority. In addition,&nb

By CPF on 2021-06-10
READ MORE→
Apixaban and Rivaroxaban

Guangzhou API exhibition in 2021

The 86th China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Fair (API China for short)Organizer: Reed Sinopharm Exhibition Co., Ltd.Exhibition time: May 26-28, 2021Venue: China Import and Export Fair Complex (Guangzhou)Exhibition scale: 60,000 square metersExhibitors:

By CPF on 2021-05-13
READ MORE→
Guangzhou API exhibition in 2021
1234
About CPF
Products & Services
R&D
News
Contact us
Adress:NO. 518 Laodong East Road, Changzhou, Jiangsu, China
Phone:+86 519 88821493
E-Mail:zhangyajuan@czpharma.com
E-Mail:shm@czpharma.com

苏ICP备14053581号-3